Trump Strikes Deals With Lilly and Novo to Cut GLP-1 Prices and Expand Coverage

Overview

• Initial oral GLP-1 doses are targeted at about $149 per month if approved, with injectables priced around $245 per month for Medicare and Medicaid patients, according to U.S. officials.
• Medicare coverage will widen to defined obesity-related groups with patient copays capped at $50 per month, while Medicaid access will expand as states opt in.
• Cash-payer discounts are slated to start by January, Medicare changes phase in by mid-2026, and TrumpRx is scheduled to launch in 2026 with starting prices below $350 and a goal of $245 within two years.
• The White House says the deals include regulatory vouchers and tariff relief, with Novo Nordisk pledging roughly $10 billion in U.S. investment and Eli Lilly committing at least $27 billion in manufacturing.
• Officials and analysts caution that out-of-pocket savings will vary because insurer formularies, commercial coverage decisions, and state Medicaid participation will determine what consumers actually pay.